Influence of magnesium sulfate on the pharmacodynamic characteristics of rocuronium. A randomized clinical trial

Background As a multimodal anesthesia adjuvant, magnesium sulfate (MgSO4) plays an important role in the anesthetic arsenal, due to its properties and substantial synergistic effects with other drugs such as opioids, hypnotics and neuromuscular blocking drugs (NMBD). Rocuronium is a non-depolarizing NMBD used widely in general anesthesia, and its association with MgSO4 is still a concern. This study aimed to evaluate the influence of MgSO4 at a dose of 30 mg kg–1 on the pharmacodynamic characteristics of rocuronium. Methods It was a double-blinded, randomized controlled trial in adult female patients scheduled for open hysterectomies with total intravenous anesthesia. Patients were allocated randomly to receive MgSO4 (30 mg kg–1) diluted in 100 mL of saline, 10 minutes before induction, or 100 mL of saline. Primary outcome: Influence of MgSO4 on latency (onset time), clinical duration (CD25%) and time to recover 90% of T4/T1 – train of four (TOF = 0.9). In total, 70 patients were enrolled, 35 per group. Results The baseline characteristics were similar. A comparative analysis showed a significant difference between the groups regarding latency in seconds (lower with MgSO4) 40.00 (35–45 [30–68]) compared to saline 53.00 (50–60 [40–90]) (P < 0.001), CD25% in minutes (longer with MgSO4) 61.00 (53–70 [30–110]), saline 38.00 (35–48 [30–87 (P <0.001), and TOF = 0.9 in minutes, longer with MgSO4 98.00 (88–111 [53–176]), saline 60.00 (55–78 [44–130]) (P < 0.001). MgSO4 was found to reduce opioid consumption in the postanesthetic care unit. Conclusions The strong impact of MgSO4 on the pharmacodynamics of rocuronium confirms the indispensable role of quantitative neuromuscular blockade monitoring to guide reversal.